Compare CarMax, Inc (KMX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Natera Inc. Common Stock — how do they compare? CarMax, Inc trades at $49.79 (market cap $7.21B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 7.9× CarMax, Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Natera Inc. Common Stock for 0 Days on average.
| KMX | NTRA | |
|---|---|---|
Market Cap | $7.21B | $57.03B |
Volume | 3,127,971 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $425.64 |
52-Week Low | $30.88 | $179.42 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $24.91B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $49.83, down 1.7% on the day, with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show attractive P/S of 0.26x but elevated P/E of 23.97x. Net income margin remains thin at 1.06%, though improving from previous quarters. The stock faces technical resistance at $51-$53 levels with RSI indicating potential oversold conditions.
KMX presents a mixed investment case with strong operational turnaround momentum but significant debt burden and margin pressures. The consensus price target of $60.63 offers 22% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include high leverage (debt-to-assets of 68.16%), cyclical auto market exposure, and execution of the 'Shift into GEAR' strategy. Near-term catalysts include the November strategic update webcast and continued earnings momentum.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
